Bitcoin price today: hits record high over $124k on rate cut bets, corporate cheer
In a recent transaction, Warren Eric, the Chief Commercial Officer of Esperion Therapeutics, Inc. (NASDAQ:ESPR), sold 2,433 shares of the company’s common stock. The shares were sold on March 18, 2025, at a price of approximately $1.487 per share, amounting to a total transaction value of $3,617. The transaction occurred as the stock trades near its 52-week low of $1.47, with the company’s market capitalization currently standing at $332 million. Following this sale, Eric retains ownership of 370,326 shares in the company. The sale was executed to satisfy tax obligations related to vested restricted stock units. According to InvestingPro data, Esperion faces significant challenges with substantial debt levels and negative earnings per share of -$0.28 over the last twelve months. For deeper insights into insider trading patterns and comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, Esperion Therapeutics reported a significant revenue increase of 114% year-over-year for the fourth quarter of 2024, reaching $69.1 million, surpassing the forecast of $63.45 million. This growth was driven by a 52% increase in U.S. net product revenue and a 227% surge in collaboration revenue. The company’s earnings per share (EPS) was reported at -$0.11, better than the anticipated -$0.14. Esperion ended the fiscal year with approximately $145 million in cash, positioning it well for future investments in its products’ commercial growth. Additionally, the company experienced a 12% sequential demand growth in U.S. net product sales, although this was partially offset by the Medicare coverage gap’s impact. Analysts at JMP maintained their Market Outperform rating for Esperion, with a price target of $4.00, citing confidence in the company’s growth trajectory and ongoing U.S. commercialization efforts. Esperion has also expanded its healthcare provider base and payer access, now covering 173 million lives in the U.S. Management expects the impact of the Medicare coverage gap on earnings to be a one-time event, with net revenue better reflecting demand growth in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.